Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

HER2+ Breast Cancer: Use of Weekly Paclitaxel-Trastuzumab

January 15th 2019

HER2+ Breast Cancer: The KATHERINE Trial

January 15th 2019

A Background on Early HER2+ Breast Cancer

January 15th 2019

Dr. Albain Discusses Race-Based Breast Cancer Study Within TAILORx

January 15th 2019

Kathy S. Albain, MD, director, Breast Clinical Research Program, co-director, Breast Oncology Center, professor of medicine, Stritch School of Medicine, Loyola University Chicago, discusses a race-based study within the TAILORx trial.

Expert Explores Future of CDK4/6 Inhibitors in Breast Cancer

January 11th 2019

Matthew P. Goetz, MD, discusses the impact of CDK4/6 inhibitors and their future role in the treatment of hormone receptor–positive breast cancer.

CDK4/6 Inhibitors Explored in Adjuvant Breast Cancer Setting

January 10th 2019

Recently, CDK 4/6 inhibitors have been changing practice in advanced HR-positive breast cancer, with 3 agents now having FDA-approved indications for use with endocrine therapy in the first-line setting.

Study Finds No Cognitive Effects From Endocrine Therapy

January 8th 2019

Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.

Dr. Corbin on Patient Selection for Proton Therapy in Breast Cancer

January 5th 2019

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Future Impact of TAILORx on Breast Cancer Management

January 3rd 2019

Race/Ethnicity and Clinical Outcomes in Breast Cancer

January 3rd 2019

Economic Impact of Oncotype DX on Breast Cancer Management

January 3rd 2019

Prognostic Value of the DCIS Score in Breast Cancer

January 3rd 2019

TAILORx: Patient-Reported Outcomes in Breast Cancer

January 3rd 2019

Dr. Leon Ferre on Emerging Therapies in TNBC

January 2nd 2019

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).

Study Addresses Breast Cancer Monitoring Burden on Metastatic Patients

January 2nd 2019

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Greater Genomic Understanding Is Gateway to Drug Development in TNBC

December 31st 2018

Leon Ferre, MD, discusses new insights into the biology of triple-negative breast cancer that may lead to the emergence of novel therapies for these patients.

Integrating PARP Inhibitors Into the Treatment of Women

December 30th 2018

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Future Roles of PARP Inhibition in Breast Cancer

December 28th 2018

PARP/Checkpoint Inhibition in TNBC: The TOPACIO Trial

December 28th 2018

Adding Olaparib to Chemotherapy in TNBC: The PARTNER Trial

December 28th 2018